All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
JEANNE HAGGERTY New on this filing

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
ROBERT BUTORA

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 7

Health Issues

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX.

Budget/Appropriations

Support for obesity drug coverage and access.

Medicare/Medicaid

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Taxation/Internal Revenue Code

Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21.

General issues related to patent protections.

Trade (domestic/foreign)

Issues related to China WRT the BINSA bill. Monitoring 232 investigations.

Defense

Issues related to China WRT the BINSA bill.

Bills named in this filing 1

H.R. 6509
SAFE Drugs Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.